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literature the differentiation between salivary gland dysfunc-
tion due to cGVHD and long-term related high dose chemo-
therapy.
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A PILOT STUDY OF MYELOABLATIVE (MA) AUTOLOGOUS STEM CELL
TRANSPLANTATION (AUTOSCT) FOLLOWED BY REDUCED INTENSITY
(RI) ALLOGENEIC TRANSPLANTATION (ALLOSCT) IN CHILDREN AND
YOUNG ADULTS WITH RELAPSED/REFRACTORY LYMPHOMA
Bradley, M.B., Cooney, E., Harrison, L., George, D., Garvin, J., Del
Toro, G., Bessmertny, O., Cheung, Y.-K., Weiner, M., Kelly, K.,
Gewanter, R., Skerrett, D., Cairo, M.S. Children’s Hospital of New
York-Presbyterian, Columbia University, New York, NY
AlloSCT may be beneﬁcial to patients with relapsed Hodgkin’s
disease (HD) and non-Hodgkin’s lymphoma (NHL) by providing
a graft vs HD effect. MA AlloSCT is however associated with a
high incidence of regimen-related mortality (RRM) (Jones et al,
Blood 77:649, 1991). Carella et al (JCO 18:3918, 2000) demon-
strated the feasibility of MA AutoSCT followed by RI AlloSCT in
adults with refractory HD. We investigated MA AutoSCT fol-
lowed by RI AlloSCT in relapsed pediatric HD/NHL. Patients
were entered post reinduction therapy (2 CR  2 PR after Ifos/
Carbo/Etop, 1 CR after Ifos/Vinorelbine and 1 PR after Topo/
Ifos/Carbo). MA: Cyclo 1500 mg/m2  4d, BCNU 100 mg/m2 
3d, VP-16 800 mg/m2  3d, and AutoSCT. Patients with CD20
lymphoma (5/6) received Rituximab (375 mg/m2/wk/4) and 6
patients received IFRT (2-3 Gy). RI: Flu 30 mg/m2  5d, Bu 3.2
mg/kg  2d, and Thymoglobulin® 2.0 mg/kg  4d (UCB recip-
ients only) and AlloSCT (1 related 6/6 PBSC, 5 4/6 UCB). GVHD
prophylaxis: FK506 (0.03 mg/kg CIVI) on day-1-60 and MMF
(15 mg/kg) day 1-28. Five HD age 13-21 yrs, 2 stage IIA, 1
stage IIIB, 1 stage IVA, 1 stage IVB and 1 stage III ALCL, age 11,
have been treated. MA AutoSCT  RI AlloSCT were well toler-
ated in all patients. Median time to RI AlloSCT after MA Auto-
SCT was 121 d. Median F/U is 577 d. Toxicity: grade 3 hematuria
(n  1), grade 3/4 infection without neutropenia (n  3), grade 4
infection with neutropenia (n  2), grade 4 pulmonary ﬁbrosis
(n 1), grade 4 hearing loss (n 1) and grade 4 thrombocytopenia
(n  1). Following RI AlloSCT, myeloid recovery occurred on day
15 (MRD), day 18, 23, 15, 30, 45 days (UCBT), plate-
let recovery on day 11 (MRD), day 31, 170, 25, 62, NE
(UCBT). All patients achieved 100% donor chimerism by d180.
HD patients: 4/5 are NED at d 837, 836, 632 (deceased) and
147, respectively, 1/5 PD d 175. NHL: NED at d 522. One
patient developed grade II AGVHD of the gut which resolved with
steroids. One patient developed limited CGVHDwhich responded
to alternating CSA  Pred. One pt developed extensive CGVHD.
There has been one death (NRM) from infection d 632. The
estimated OS at 1 year is 100%. In summary, MA  AutoSCT
followed by IFRT, targeted monoclonal antibody therapy, and RI
AlloSCT is feasible and well tolerated in pediatric patients with
relapsed HD/NHL. A larger controlled study with longer follow
up is required to determine if this approach will reduce relapse
and/or long-term toxicity and improve EFS.
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PERSISTENTLY LOW SERUM OSTEOPROTEGRIN LEVELS DURING THE
TREATMENT OF MULTIPLE MYELOMA PATIENTS PREDICTS WORSE
EVENT-FREE SURVIVAL
Moreb, J.S., Zucali, J.R., Roberts, C. University of Florida, Gainesville,
FL
Osteoprotegrin (OPG) functions as a secreted inhibitor of bone
resorption and its serum levels have been reported to be reduced in
patients with multiple myeloma (MM). In this study, serum and
urine OPG levels were prospectively measured in patients with
MM (stage II III) and in patients with other hematologic malig-
nancies (control group) and correlated to response to therapy.
Newly diagnosed as well as patients on maintenance therapy were
included. The MM and control group were well matched in terms
of age and gender, as well as time from diagnosis to enrollment.
Seventeen MM patients underwent autologous stem cell transplant
while none in the control group were transplanted. Blood and
urine samples were collected monthly, cytocentrifuged and stored
in frozen aliquots at 20° C until analyzed. OPG was measured
using an ELISA. Thus far data on 28 MM patients and 9 patients
with other hematologic malignancies (2 AML, 2 CML, 1 CLL, 2
NHL, 2 monoclonal gammopathy of unknown signiﬁcance) have
been analyzed. All patients were treated with monthly intravenous
bisphosphonate. The results reveal that OPG is detectable in the
urine and its levels correlate signiﬁcantly (r  0.77 and two-tailed
P  0.0032) with the degree of renal failure as reﬂected by serum
creatinine. Our results also show that the overall median serum
OPG level was lower in MM patients (1181 pg/mL), but not
signiﬁcantly different than that of the control group (1437 pg/mL).
However, 4 of 20 (20%) evaluable MM patients with adequate
follow-up had OPG serum levels that remained  1000 pg/mL
throughout the treatment. Their median event-free survival (EFS)
was 8 months compared with 19 months for the rest of the group
(P  0.023), while no signiﬁcant difference was detected in the
median overall survival. There was no OPG serum levels  1000
pg/mL during the follow-up of the control group. Among the 10
newly diagnosed MM patients enrolled in the study, only 2 (20%)
had low serum OPG at presentation, with no detectable urine
OPG. Median OPG serum levels were lower for MM patients
during induction therapy (940 pg/mL, n  7) in comparison to
those undergoing maintenance therapy (1536 pg/mL, n  8; P 
0.16). In conclusion, OPG urine as well as serum levels should be
monitored simultaneously since low serum levels may reﬂect high
OPG urinary loss. In addition, persistently low OPG serum levels
throughout treatment of MM patients may be a prognostic factor
for worse EFS.
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ASCT IN A YOUNG PATIENT WITH FEATURES OF POEMS SYNDROME
EVOLVING TO MULTIPLE MYELOMA
Roesler, W., Guenther, A., Schub, N., Winkler, J., Rascu, A., Repp, R.,
Gramatzki, M. Div. of Hematology/Oncology, Department of Medicine
III, University of Erlangen-Nuremberg, Erlangen, Germany
POEMS syndrome is a rare plasma cell dyscrasia characterised by
polyneuropathy, organomegaly, endocrinopathy, monoclonal
gammopathy and skin changes. The pathogenesis of the disease is
unclear. However, certain features are similar to multicentric
Castleman’s disease and HHV-8 infection. We report the case of a
patient with POEMS syndrome progressing to multiple myeloma
that was unresponsive to treatment with rituximab and standard
chemotherapy but improved considerably after ASCT. The 28 year
old patient presented with severe polyneuropathy. A low level IgG
lamda monoclonal gradient and a slight plasma cell inﬁltration of
the marrow was found. Hepatosplenomegaly, thrombocytosis,
polycythemia, plethora and low TSH was consistent with POEMS
syndrome. The patient had anti-HHV-8 antibodies and HHV-8-
DNA was found in her initial marrow examination. While reported
to be effective in Castleman’s disease, the patient was treated with
4 doses of rituximab, but did not respond. During the following 3
months the patient progressed to multiple myeloma with a bone
marrow involvement of  20% plasma cells. Atypical plasma cells
and a hypercellular megakaryopoesis were found. However, no
Table. Preliminary Results of Gallium-67 Scintigraphic Study on
Major Salivary Glands (n  18 patients)
Submandible
(n patients)
Parotid
(n patients)
Positive Negative Positive Negative
Before BMT 1 17 0 18
Day 30 after 5 9 3 11
Day  60 after 7 6 3 10
Day  100 after 7 6 4 9
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